Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Xing-Yu Cao"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
This is the first report of NUP98::LEDGF positive malignant hematological tumor expressing T cell and myeloid lineage antigens. Patients carrying this fusion gene have a high relapse rate and a poor prognosis, allo-HSCT may be an option to cure this
Externí odkaz:
https://doaj.org/article/1230b9df22e84f24b9f0ad3a04f3281e
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionThe human leukocyte antigen (HLA) evolutionary divergence (HED) reflects immunopeptidome diversity and has been shown to predict the response of tumors to immunotherapy. Its impact on allogeneic hematopoietic stem cell transplantation (HS
Externí odkaz:
https://doaj.org/article/274514776a674a298a6f67f2f7dded03
Autor:
Xing-yu Cao, Jia-qi Chen, Hui Wang, Wei Ma, Wei-wei Liu, Fang-fang Zhang, Song Xue, Lei Dong, Ting Liu, Xiao-zhen Zhao, Chan-chan Liu, Xin Xu, Yang He, Lei Wang, Jian-ling Wang
Publikováno v:
Annals of Medicine, Vol 55, Iss 1, Pp 388-400 (2023)
AbstractBackground Venetoclax monotherapy is an effective option for patients with acute myeloid leukemia (AML). Venetoclax has also been used in non-myeloablative conditioning allogeneic hematopoietic stem cell transplantation (allo-HSCT) for high-r
Externí odkaz:
https://doaj.org/article/a3a0c37f50f84a2584cf1ea8f33e943a
Autor:
Xing-yu Cao, Jian-ping Zhang, Yan-li Zhao, Min Xiong, Jia-rui Zhou, Yue Lu, Rui-juan Sun, Zhi-jie Wei, De-yan Liu, Xian Zhang, Jun-fang Yang, Peihua Lu
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundChimeric antigen receptor (CAR) T-cell therapy has demonstrated high initial complete remission (CR) rates in B-cell acute lymphoblastic leukemia (B-ALL) patients, including those who relapsed after transplant. However, the duration of remi
Externí odkaz:
https://doaj.org/article/de62471a3fff4ba0ae5c1b7ad85c5ea8
Autor:
Yue Lu, Jian-Ping Zhang, Yan-Li Zhao, Min Xiong, Rui-Juan Sun, Xing-Yu Cao, Zhi-Jie Wei, Jia-Rui Zhou, De-Yan Liu, Jun-Fang Yang, Xian Zhang, Dao-Pei Lu, Peihua Lu
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
IntroductionWe aimed to evaluate prognostic factors of a second allogeneic stem cell transplantation (allo-HSCT2) among hematological malignancy patients who have relapsed after the first allo-HSCT(allo-HSCT1).MethodsWe retrospectively analyzed 199 h
Externí odkaz:
https://doaj.org/article/a2f5b81ae7ee491493a8d106d48e8263
Autor:
Yan-Li Zhao, De-Yan Liu, Rui-Juan Sun, Jian-Ping Zhang, Jia-Rui Zhou, Zhi-Jie Wei, Min Xiong, Xing-Yu Cao, Yue Lu, Jun-fang Yang, Xian Zhang, Dao-Pei Lu, Peihua Lu
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Patients often undergo consolidation allogeneic hematopoietic stem cell transplantation (allo-HSCT) to maintain long-term remission following chimeric antigen receptor (CAR) T-cell therapy. Comparisons of safety and efficacy of allo-HSCT following co
Externí odkaz:
https://doaj.org/article/e7b8b7472bc84b5899d8b0e22ecf0259
Autor:
Yue Lu, Min Xiong, Rui-Juan Sun, Jian-Ping Zhang, Yan-Li Zhao, Zhi-Jie Wei, Xing-Yu Cao, Jia-Rui Zhou, De-Yan Liu, Dao-Pei Lu
Publikováno v:
Leukemia & Lymphoma. 63:3307-3316
We retrospectively analyzed the outcomes of 240 pediatric SAA patients who underwent unmanipulated alternative HSCT between September 2012 and November 2020 at our center. The incidence of GF (PGF + SGF) was higher in the UCBD cohort compared to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b090717fcdd889d2f1446be856191d8
https://doi.org/10.1080/10428194.2022.2118527
https://doi.org/10.1080/10428194.2022.2118527
Autor:
Yue Lu, Dao-Pei Lu, Yan-Li Zhao, Jian-Ping Zhang, De-Yan Liu, Zhi-Jie Wei, Rui-Juan Sun, Jia-Rui Zhou, Xing-Yu Cao, Min Xiong
Publikováno v:
Hematology. 26:134-143
Objective: The outcomes of alternative donor hematopoietic stem cell transplantation (HSCT) with unmanipulated grafts for Inherited bone marrow failure syndromes (IBMFS) are discouraging. Our study...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ddf94816d394ebb4430e1d78dee6e43
https://doi.org/10.1080/16078454.2021.1876393
https://doi.org/10.1080/16078454.2021.1876393
Autor:
Xing-yu Cao, Jian-Ping Zhang, Yan-Li Zhao, Min Xiong, Jiarui Zhou, Yue Lu, Ruijuan Sun, Zhijie Wei, Deyan Liu, Xian Zhang, Junfang Yang, Peihua Lu
Publikováno v:
Blood. 140:4802-4803
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b068adcc9be8f0c44b1ac85b6d0bb05
https://doi.org/10.1182/blood-2022-166993
https://doi.org/10.1182/blood-2022-166993
Publikováno v:
Leukemialymphoma. 63(5)
We analyzed the outcomes of 32 patients with paroxysmal nocturnal hemoglobinuria (PNH) who underwent either a haploidentical donor (HID) or a matched unrelated donor (MUD) hematopoietic stem cell transplantation (HSCT). Seventeen patients received an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45549548adc7457644977ef4e309b453
https://pubmed.ncbi.nlm.nih.gov/34913818
https://pubmed.ncbi.nlm.nih.gov/34913818